These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 32266704)

  • 1. Eptinezumab: First Approval.
    Dhillon S
    Drugs; 2020 May; 80(7):733-739. PubMed ID: 32266704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
    Hargreaves R; Olesen J
    Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC; Schwedt TJ
    Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erenumab: First Global Approval.
    Markham A
    Drugs; 2018 Jul; 78(11):1157-1161. PubMed ID: 29968151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications.
    Dodick DW
    Cephalalgia; 2019 Mar; 39(3):445-458. PubMed ID: 30661365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigens and Antibodies in Disease With Specifics About CGRP Immunology.
    Taylor FR
    Headache; 2018 Nov; 58 Suppl 3():230-237. PubMed ID: 30187471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rimegepant: First Approval.
    Scott LJ
    Drugs; 2020 May; 80(7):741-746. PubMed ID: 32270407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Insights into the Regulation of CGRP-Family Receptors.
    Gingell JJ; Hendrikse ER; Hay DL
    Trends Pharmacol Sci; 2019 Jan; 40(1):71-83. PubMed ID: 30527443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting calcitonin gene-related peptide: a new era in migraine therapy.
    Charles A; Pozo-Rosich P
    Lancet; 2019 Nov; 394(10210):1765-1774. PubMed ID: 31668411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine.
    Maasumi K; Michael RL; Rapoport AM
    Drugs; 2018 Jun; 78(9):913-928. PubMed ID: 29869205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CGRP as the target of new migraine therapies - successful translation from bench to clinic.
    Edvinsson L; Haanes KA; Warfvinge K; Krause DN
    Nat Rev Neurol; 2018 Jun; 14(6):338-350. PubMed ID: 29691490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine.
    Pederson S; Biondi DM; Allan B; Cady R; Schaeffler B; Baker B; Latham J
    Front Immunol; 2021; 12():765822. PubMed ID: 34759933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new era for migraine: The role of calcitonin gene-related peptide in the trigeminovascular system.
    Chen ST; Wu JW
    Prog Brain Res; 2020; 255():123-142. PubMed ID: 33008504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eptinezumab for the preventive treatment of migraine.
    Villar-Martínez MD; Moreno-Ajona D; Goadsby PJ
    Pain Manag; 2021 Mar; 11(2):113-121. PubMed ID: 33280422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CGRP Pathway in Migraine as a Viable Target for Therapies.
    Edvinsson L
    Headache; 2018 May; 58 Suppl 1():33-47. PubMed ID: 29697153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development.
    Bigal ME; Walter S; Rapoport AM
    Headache; 2013 Sep; 53(8):1230-44. PubMed ID: 23848260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eptinezumab for the treatment of migraine.
    Scuteri D; Corasaniti MT; Tonin P; Bagetta G
    Drugs Today (Barc); 2019 Nov; 55(11):695-703. PubMed ID: 31840684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update.
    Charles AC; Digre KB; Goadsby PJ; Robbins MS; Hershey A;
    Headache; 2024 Apr; 64(4):333-341. PubMed ID: 38466028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical aspects of novel CGRP inhibitors used in the prophylaxis and treatment of migraine.
    Jinesh S
    Inflammopharmacology; 2023 Oct; 31(5):2245-2251. PubMed ID: 37421480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.